NCT03808077View on ClinicalTrials.gov

The Effect of Deep Versus Moderate Muscle Relaxants in Men During and After Robotic Surgery for Prostate Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

139

Participants

Timeline

Start Date

January 14, 2019

Primary Completion Date

October 11, 2024

Study Completion Date

January 31, 2026

Conditions
Prostate Cancer
Interventions
DRUG

Rocuronium 0.3mg/kg/hr

The Moderate NMB group (Control ) will have rocuronium infusion titrated to moderate paralysis defined as TOF of 1-2 (infusion start rate 0.003 mg/kg/min or 0.18mg/kg/hr).

DRUG

Rocuronium 1.5mg/kg/hr

The Deep NMB group (Intervention) will have rocuronium infusion titrated to deep paralysis defined as PTC of 1-2 (infusion start rate 0.006mg/kg/min or 0.35mg/kg/hr).

Trial Locations (1)

10065

Memorial Sloan Kettering Cancer Center, New York

All Listed Sponsors
lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT03808077 - The Effect of Deep Versus Moderate Muscle Relaxants in Men During and After Robotic Surgery for Prostate Cancer | Biotech Hunter | Biotech Hunter